Publications by authors named "A Kourakli"
Proteasome inhibitors (PIs) constitute the most common type of induction treatment for multiple myeloma. Interactions between the proteasome, autophagy, and reactive oxygen species (ROS) have been shown in the past, thus emphasizing the need for a better understanding of the underlying pathophysiology. For this study, bone marrow mononuclear cells from 110 myeloma patients were collected at different disease stages.
View Article and Find Full Text PDFBackground: As new treatment options for patients with higher-risk myelodysplastic syndromes are emerging, identification of prognostic markers for hypomethylating agent (HMA) treatment and understanding mechanisms of their delayed and short-term responses are essential. Early fetal hemoglobin (HbF) induction has been suggested as a prognostic indicator for decitabine-treated patients. Although epigenetic mechanisms are assumed, responding patients' epigenomes have not been thoroughly examined.
View Article and Find Full Text PDFA Nationwide Study of the Delayed Diagnosis and the Clinical Manifestations of Predominantly Antibody Deficiencies and -Mediated Immune Dysregulation Syndrome in Greece.
Medicina (Kaunas)
May 2024
Article Synopsis
- Predominantly antibody deficiencies (PAD) are the most common type of immune problems in people, but it's not well-known how many people have them in Greece.
- A study was done on 153 patients to learn more about these deficiencies, and they found different types of PAD among the patients.
- The study showed that it often took a long time (about 9 years) for people to be diagnosed with PAD after they first noticed symptoms, and many of the patients had more serious health issues like infections and even cancer.
The assessment of health-related quality of life (HRQoL) in thalassemia offers a holistic approach to the disease and facilitates better communication between physicians and patients. This study aimed to evaluate the HRQoL of transfusion-dependent thalassemia (TDT) patients in Greece. This was a multicentric, cross-sectional study conducted in 2017 involving 283 adult TDT patients.
View Article and Find Full Text PDFGiven the limited real-world data of caplacizumab, our multicenter real-world study was designed to assess the safety and efficacy of caplacizumab in immune thrombotic thrombocytopenic pupura (iTTP), compared to historic controls. We have studied 70 patients: 23 in the caplacizumab and 47 in the historic control group. Plasma exchange was applied in all episodes except for two patients that denied plasma exchange.
View Article and Find Full Text PDF